Product Reports Resources Pricing Login Book a demo

Harbour BioMed

Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibody therapeutics for oncology and immunology. The company develops its portfolio and pipeline through internal research and development, collaborations, and acquisitions. Its proprietary antibody technology platforms, Harbour Mice®, generate fully human monoclonal antibodies in two formats: H2L2 and heavy chain only (HCAb). The HCAb-based immune cell engagers (HBICE®) are designed to deliver tumor-killing effects that are not achievable with traditional combination therapies. The integration of Harbour Mice® with a single B cell cloning platform provides an efficient antibody discovery engine for developing next-generation therapeutic antibodies. Keywords: biopharmaceutical, antibody therapeutics, oncology, immunology, monoclonal antibodies, Harbour Mice, HBICE, H2L2, HCAb, B cell cloning

Valuation $926M
Revenue $202M
EBITDA $95M
Total funding $100–500M
Power Law Thoroughbred$100M+ revenue

Investors

20 investors on Harbour BioMed's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 13 investors entered at this stage
Legend Capital
Advantech Capital
GIC
Cambridge University Endowment Fund (CUEF)
Vertex Holdings
Sovereign Wealth Funds
China Life Private Equity Investment
Zheshang Venture Capital
SK Group
Efung Capital
Zhejiang University Future Capital
Greater Bay Area Fund
JT New Century
Series B+ 7 investors entered at this stage
Hudson Bay Capital Management
OrbiMed
ShenZhen GTJA Investment Group
Octagon Capital Partners
Sage Partners
Country Garden
AstraZeneca

Global footprint

Where Harbour BioMed has talent and traffic

Workforce by country
5 countries with
team presence
🇨🇳 China76.5%
🇺🇸 United States19.8%
🇭🇰 Hong Kong1.2%
🇳🇱 Netherlands1.2%
🇬🇧 United Kingdom1.2%
5 countries shown
Web traffic by country
4.5K monthly visits
across markets
🇺🇸 United States66.7%
🇮🇳 India15.6%
🇨🇦 Canada13.3%
🇭🇰 Hong Kong4.4%
Top 4 markets shown

Talent graph

The shape of Harbour BioMed's talent

Dealroom maps Harbour BioMed's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom
114 employeestotal headcount
2 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Harbour BioMed's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$48M patent portfolio · 89 active families

Estimated portfolio value
$48M
5.1% of market cap · 6.6× smaller than top peer Pacific Biosciences ($314M)
89 active patent families
Where Harbour BioMed innovates Antigen Binding FragmentBinding proteinAntibodyAntiendomysial antibodiesAntigen

Where Harbour BioMed concentrates vs peers

Each axis is a top-10 topic across Harbour BioMed and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Harbour BioMed

An AI-synthesized read of the highest-engagement posts about Harbour BioMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harbour BioMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles